Tempus AI (NASDAQ:TEM) Stock Price Up 4.2% – Time to Buy?

Tempus AI, Inc. (NASDAQ:TEM) shares traded up 4.2% during trading on Tuesday . The stock traded as high as $47.23 and last traded at $47.08. 3,436,270 shares changed hands during trading, a decline of 28% from the average session volume of 4,804,807 shares. The stock had previously closed at $45.17.

Analyst Upgrades and Downgrades

TEM has been the topic of several research analyst reports. Wolfe Research downgraded Tempus AI from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, February 26th. Morgan Stanley raised their price target on Tempus AI from $50.00 to $60.00 and gave the stock an “overweight” rating in a report on Thursday, March 6th. Loop Capital decreased their price objective on shares of Tempus AI from $57.00 to $52.00 and set a “buy” rating for the company in a research report on Tuesday, January 14th. TD Cowen reissued a “buy” rating and set a $74.00 target price (up previously from $58.00) on shares of Tempus AI in a research report on Wednesday, February 5th. Finally, Guggenheim reaffirmed a “buy” rating on shares of Tempus AI in a report on Tuesday, February 25th. Six investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $61.18.

Tempus AI Trading Down 7.3 %

The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 8.17. The stock’s 50 day moving average price is $55.00 and its two-hundred day moving average price is $51.98.

Insiders Place Their Bets

In other Tempus AI news, EVP Andrew Polovin sold 1,130 shares of the company’s stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $40.23, for a total value of $45,459.90. Following the sale, the executive vice president now owns 244,955 shares in the company, valued at approximately $9,854,539.65. This represents a 0.46 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CAO Ryan M. Bartolucci sold 13,770 shares of the firm’s stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $60.00, for a total transaction of $826,200.00. Following the sale, the chief accounting officer now directly owns 57,237 shares in the company, valued at $3,434,220. The trade was a 19.39 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 5,755,906 shares of company stock valued at $322,788,693.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Sigma Planning Corp acquired a new stake in shares of Tempus AI during the 3rd quarter valued at about $1,323,000. GSA Capital Partners LLP purchased a new position in Tempus AI during the third quarter worth approximately $306,000. Sumitomo Mitsui Trust Group Inc. boosted its position in Tempus AI by 1,591.2% during the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,217,699 shares of the company’s stock worth $68,922,000 after purchasing an additional 1,145,698 shares in the last quarter. First Horizon Advisors Inc. acquired a new stake in Tempus AI in the third quarter valued at approximately $30,000. Finally, The Manufacturers Life Insurance Company increased its position in shares of Tempus AI by 10.2% in the third quarter. The Manufacturers Life Insurance Company now owns 29,789 shares of the company’s stock valued at $1,686,000 after buying an additional 2,765 shares in the last quarter. Institutional investors and hedge funds own 24.22% of the company’s stock.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.